Reconnecting

The current page stays visible while onset.to reconnects in the background.

onset.to

← All weeks

Highlights Aug 10 - Aug 16, 2026

new every Sunday

This week paired early therapeutic signals with sharper attention to safety, regulation, and stewardship. New work ranged from postpartum depression and ibogaine analogs to specialized aftercare and Gabon's control over iboga.

  1. 01 5-MeO-DMT zeigt in einer ersten klinischen Studie Potenzial gegen postpartale Depression mit rascher Wirkung und anhaltender Symptomverbesserung

    A first clinical study linked 5-MeO-DMT to rapid, sustained improvement in postpartum depression, but controlled trials are still needed.

    psypost.org · Aug 10, 2026 5-MeO-DMT Clinical
  2. 02 First-of-its-kind clinic treats psychedelic side effects as more people seek help for lingering anxiety, perceptual changes, trauma, and spiritual distress

    A specialized clinic is treating persistent anxiety, perceptual changes, trauma, and spiritual distress after psychedelic use.

    scientificamerican.com · Aug 11, 2026 Unspecified Safety
  3. 03 Engineered psychedelic analog in mice retains antidepressant-like and anti-inflammatory effects while avoiding the severe gastrointestinal distress seen with ibogaine

    Mouse data suggest an ibogaine analog may retain antidepressant-like and anti-inflammatory effects without severe gastrointestinal distress.

    psypost.org · Aug 12, 2026 Ibogaine Research
  4. 04 MAPS addresses progress in FDA discussions on MDMA-assisted therapy for PTSD and outlines regulatory steps, safety oversight, and the path toward potential resubmission

    MAPS details the evidence, safety oversight, and regulatory steps that could determine whether MDMA-assisted therapy returns to the FDA.

    maps.org · Aug 10, 2026 MDMA Clinical
  5. 05 Gabon places ibogaine policy within national sovereignty, cultural stewardship, and global demand as international interest in iboga-derived medicine accelerates

    Gabon frames iboga policy around sovereignty, conservation, cultural ownership, and benefit sharing as international demand grows.

    psychedelicstoday.com · Aug 10, 2026 Ibogaine Policy
  6. 06 5-HT2A-Rezeptoraktivierung verstärkt in präklinischen Darmkrebsmodellen die antitumorale Immunantwort und deutet auf ein neues onkologisches Wirkprinzip hin

    Preclinical colon cancer models suggest 5-HT2A activation can strengthen antitumor immunity, opening a possible new oncology pathway.

    psychedelia-stiftung.de · Aug 13, 2026 Unspecified Research
  7. 07 Can magic mushrooms help treat cocaine dependence? Psilocybin is being studied as a therapy that may reduce craving, relapse risk, and compulsive drug use

    Early psilocybin research for cocaine dependence is testing effects on craving, compulsive use, relapse risk, and behavior change.

    scientificamerican.com · Aug 10, 2026 Psilocybin Research